Pioglitazone, a thiazolidinedione derivative, is an anti‐diabetic (insulin‐sensitizing) agent and selective agonist for peroxisome proliferator‐activated receptor (PPAR)‐γ, a transcription factor that regulates gene expression in the liver, adipose, vascular endothelium, and muscle tissue, and improves insulin action, glucose metabolism, inflammation, and adipocyte biology in type 2 diabetic patients with insulin resistance (Chiarelli & Di Marzio, 2008). This evidence concerns the gene INS and Insulin resistance.